Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hologene 5 for Junctional Epidermolysis Bullosa
NCT05111600Phase 3Terminated
- Sponsor
- Holostem
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Countries
- 2
01
Overview
A Phase 3 trial of Hologene 5 in junctional epidermolysis bullosa (JEB), sponsored by Holostem. Started Jul 2022; status: terminated.
02
Drugs
Hologene 5
03
Conditions
junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on NCT05111600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111600.